Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04948203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2025 to Dec 2026v9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  3. Primary and study completion dates: Jun 2024 to Dec 2025v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary and study completion dates: Jun 2022 to Jun 2024v5
Show 3 earlier versionsHide 3 earlier versions
  1. Phase: Early Phase 1 to Phase 2/3v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2021 to Jul 9, 2021
    • Site details revised
    v3
  3. Start date: Jun 2021 to Jul 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Trial Details
NCT Number NCT04948203
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Related terms Post-Acute COVID-19 Syndrome, Pulmonary Fibrosis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov